BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28424415)

  • 1. Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients.
    Chan TS; Lee YS; Del Giudice I; Marinelli M; Ilari C; Cafforio L; Guarini A; Tan D; Phipps C; Goh YT; Hwang W; Goh AZ; Siu LL; Wu S; Ha CY; Lin SY; Kwok CH; Lau CK; Wong KF; Foà R; Kwong YL; Tse E
    Oncotarget; 2017 Apr; 8(15):25455-25468. PubMed ID: 28424415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia.
    Shi K; Sun Q; Qiao C; Zhu H; Wang L; Wu J; Wang L; Fu J; Young KH; Fan L; Xia Y; Xu W; Li J
    Cancer Med; 2020 Feb; 9(3):999-1007. PubMed ID: 31849198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive assessment of prognostic factors predicting outcome in Chinese patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide.
    Xu M; Fan L; Miao KR; Liu P; Xu W; Li JY
    Med Oncol; 2012 Sep; 29(3):2102-10. PubMed ID: 21881978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic lymphocytic leukemia in a young population.
    Alshemmari SH; Hamdah A; Pandita R; Kunhikrishnan A
    Leuk Res; 2021 Nov; 110():106668. PubMed ID: 34492597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia.
    Li H; Yi SH; Xiong WJ; Liu HM; Lyu R; Wang TY; Liu W; Zhong SZ; Yu Z; Zou DH; Xu Y; An G; Li ZJ; Qiu LG
    Chin Med J (Engl); 2017 Jan; 130(2):135-142. PubMed ID: 28091403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.
    Kreuzberger N; Damen JA; Trivella M; Estcourt LJ; Aldin A; Umlauff L; Vazquez-Montes MD; Wolff R; Moons KG; Monsef I; Foroutan F; Kreuzer KA; Skoetz N
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD012022. PubMed ID: 32735048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Mistry H; Nduka C; Connock M; Colquitt J; Mantopoulos T; Loveman E; Walewska R; Mason J
    Pharmacoeconomics; 2018 Apr; 36(4):399-406. PubMed ID: 29222670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients.
    Hu B; Patel KP; Chen HC; Wang X; Luthra R; Routbort MJ; Kanagal-Shamanna R; Medeiros LJ; Yin CC; Zuo Z; Ok CY; Loghavi S; Tang G; Tambaro FP; Thompson P; Burger J; Jain N; Ferrajoli A; Bose P; Estrov Z; Keating M; Wierda WG
    Br J Haematol; 2019 Nov; 187(3):307-318. PubMed ID: 31243771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia.
    Gladstone DE; Blackford A; Cho E; Swinnen L; Kasamon Y; Gocke CD; Griffin CA; Bolaños-Meade J; Jones RJ
    Clin Lymphoma Myeloma Leuk; 2012 Apr; 12(2):132-7. PubMed ID: 22285608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
    Tausch E; Schneider C; Robrecht S; Zhang C; Dolnik A; Bloehdorn J; Bahlo J; Al-Sawaf O; Ritgen M; Fink AM; Eichhorst B; Kreuzer KA; Tandon M; Humphrey K; Jiang Y; Schary W; Bullinger L; Mertens D; Lurà MP; Kneba M; Döhner H; Fischer K; Hallek M; Stilgenbauer S
    Blood; 2020 Jun; 135(26):2402-2412. PubMed ID: 32206772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia.
    Cherng HJ; Jammal N; Paul S; Wang X; Sasaki K; Thompson P; Burger J; Ferrajoli A; Estrov Z; O'Brien S; Keating M; Wierda WG; Jain N
    Br J Haematol; 2021 Jul; 194(1):61-68. PubMed ID: 33973230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data.
    International CLL-IPI working group
    Lancet Oncol; 2016 Jun; 17(6):779-790. PubMed ID: 27185642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytogenetic characteristics of B cell chronic lymphocytic leukemia in 275 Chinese patients by fluorescence in situ hybridization: a multicenter study.
    Lai YY; Huang XJ
    Chin Med J (Engl); 2011 Aug; 124(16):2417-22. PubMed ID: 21933580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients.
    Monti P; Lionetti M; De Luca G; Menichini P; Recchia AG; Matis S; Colombo M; Fabris S; Speciale A; Barbieri M; Gentile M; Zupo S; Dono M; Ibatici A; Neri A; Ferrarini M; Fais F; Fronza G; Cutrona G; Morabito F
    Sci Rep; 2020 Oct; 10(1):18427. PubMed ID: 33116240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.
    Davids MS; Brander DM; Kim HT; Tyekucheva S; Bsat J; Savell A; Hellman JM; Bazemore J; Francoeur K; Alencar A; Shune L; Omaira M; Jacobson CA; Armand P; Ng S; Crombie J; LaCasce AS; Arnason J; Hochberg EP; Takvorian RW; Abramson JS; Fisher DC; Brown JR;
    Lancet Haematol; 2019 Aug; 6(8):e419-e428. PubMed ID: 31208944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fluorescent in situ hybridization with a panel of probes detects molecular cytogenetic abnormalities in patients with chronic lymphocytic leukemia].
    Xu W; Li JY; Li L; Yu H; Shen QD; Fan L; Qiao C; Hong M; Qian SX; Qiu HX
    Zhonghua Yi Xue Za Zhi; 2008 Sep; 88(36):2537-40. PubMed ID: 19080644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct immunoglobulin heavy chain variable region gene repertoire and lower frequency of del(11q) in Taiwanese patients with chronic lymphocytic leukaemia.
    Huang YJ; Kuo MC; Chang H; Wang PN; Wu JH; Huang YM; Ma MC; Tang TC; Kuo CY; Shih LY
    Br J Haematol; 2019 Oct; 187(1):82-92. PubMed ID: 31230372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.
    Thompson PA; O'Brien SM; Wierda WG; Ferrajoli A; Stingo F; Smith SC; Burger JA; Estrov Z; Jain N; Kantarjian HM; Keating MJ
    Cancer; 2015 Oct; 121(20):3612-21. PubMed ID: 26193999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal B-cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early-stage CLL.
    Kern W; Bacher U; Haferlach C; Dicker F; Alpermann T; Schnittger S; Haferlach T
    Br J Haematol; 2012 Apr; 157(1):86-96. PubMed ID: 22224978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry.
    Mato A; Nabhan C; Kay NE; Lamanna N; Kipps TJ; Grinblatt DL; Flowers CR; Farber CM; Davids MS; Kiselev P; Swern AS; Bhushan S; Sullivan K; Flick ED; Sharman JP
    Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):114-124.e2. PubMed ID: 29352719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.